These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Breast cancer in men: should aromatase inhibitors become first-line hormonal treatment?
    Author: Nordman IC, Dalley DN.
    Journal: Breast J; 2008; 14(6):562-9. PubMed ID: 19000052.
    Abstract:
    Breast cancer is an uncommon malignancy in men; therefore, the approach to treatment is mostly modeled on that used in females. First-line use of aromatase inhibitors (AIs) is now standard practice in hormone-sensitive metastatic breast cancer in postmenopausal females. However, tamoxifen continues to be regarded as first-line treatment in hormone-sensitive male breast cancer. This article reviews the role of second and third generation AIs as first- or second-line hormonal treatment in male patients with metastatic breast cancer. It also explores the potential use of AIs in combination with gonadotropin-releasing hormone analogs or trastuzumab suggesting that in the future this may prove a useful alternative to tamoxifen.
    [Abstract] [Full Text] [Related] [New Search]